Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TELA Bio (TELA) EBIT Margin (2018 - 2026)

TELA Bio has reported EBIT Margin over the past 8 years, most recently at 91.05% for Q4 2025.

  • For Q4 2025, EBIT Margin fell 971.0% year-over-year to 91.05%; the TTM value through Dec 2025 reached 10.1%, up 141.0%, while the annual FY2025 figure was 10.1%, 141.0% up from the prior year.
  • EBIT Margin for Q4 2025 was 91.05% at TELA Bio, up from 36.51% in the prior quarter.
  • Over five years, EBIT Margin peaked at 100.76% in Q4 2024 and troughed at 123.69% in Q1 2021.
  • A 5-year average of 59.64% and a median of 72.07% in 2023 define the central range for EBIT Margin.
  • Biggest five-year swings in EBIT Margin: soared 17300bps in 2024 and later plummeted -2748bps in 2025.
  • Year by year, EBIT Margin stood at 91.4% in 2021, then increased by 11bps to 81.22% in 2022, then grew by 11bps to 72.23% in 2023, then surged by 240bps to 100.76% in 2024, then fell by -10bps to 91.05% in 2025.
  • Business Quant data shows EBIT Margin for TELA at 91.05% in Q4 2025, 36.51% in Q3 2025, and 44.96% in Q2 2025.